{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:07:55Z","timestamp":1749683275147,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Allergan plc"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ijantimicag.2017.01.043","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T19:15:50Z","timestamp":1496776550000},"page":"247-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point"],"prefix":"10.1016","volume":"50","author":[{"suffix":"Jr","given":"Thomas M.","family":"File","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6133-9057","authenticated-orcid":false,"given":"Paul B.","family":"Eckburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George H.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. David","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0010","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis","volume":"330","author":"Mills","year":"2005","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ijantimicag.2017.01.043_bib0020","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults","author":"Eliakim-Raz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/QCO.0000000000000250","article-title":"Macrolide therapy of pneumonia: is it necessary, and how does it help?","volume":"29","author":"Restrepo","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0035","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"Beta-lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0040","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cis566","volume":"55","author":"Talbot","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0045","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/cid\/cis567","article-title":"A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia","volume":"55","author":"Toerner","year":"2012","journal-title":"Clin Infect Dis"},{"author":"US Food and Drug Administration","key":"10.1016\/j.ijantimicag.2017.01.043_bib0050"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0055","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0060","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0065","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1378\/chest.125.5.1888","article-title":"Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia","volume":"125","author":"File","year":"2004","journal-title":"Chest"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2017.01.043_bib0070","first-page":"iii1","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0075","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0080","first-page":"1699","article-title":"Atypical pathogens and challenges in community-acquired pneumonia","volume":"69","author":"Thibodeau","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.idc.2012.11.005","article-title":"Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?","volume":"27","author":"File","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?","volume":"55","author":"Amsden","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.043_bib0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.2012.02554.x","article-title":"Treatment with anti-inflammatory drugs in community-acquired pneumonia","volume":"272","author":"Meijvis","year":"2012","journal-title":"J Intern Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T22:57:53Z","timestamp":1535756273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0924857917301796"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.043","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}